Preview

Симпатическая нервная система, ожирение и артериальная гипертензия. Возможности терапии

https://doi.org/10.14341/2071-8713-5016

Полный текст:

Об авторе

A O Konradi



Список литературы

1. Montani J.P., Antic V., Yang Z., Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Obesity. 2002; 26 (Suppl. 2):S28-S38.

2. Triosi R.L., Weiss ST., Parker D.R. et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991; 14:669-677.

3. Sowers J.R., Nyby M., Stern N. et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension. 1982; 4:686-691.

4. Vas M., Jennings G., Turmer A. et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997; 96:3423-3429.

5. Rumantir M.S., Vas M., Jennings G. et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999; 17:1125-1133.

6. Grassi G., Vailati S., Bertinieri G. et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639.

7. Scherrer U., Randin D., Tappy D.R. et al. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994; 82:2634-2640.

8. Grassi G., Seravalle G., Dell'Oro R. et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538-542.

9. Grassi G., Dell'oro R., Facchini A. et al. Effect of central and peripheral fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-2369.

10. Alvarez G.E., Beske S.D., Ballard T.P., Davy K.P. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533-2536.

11. Landsberg L.,Young J.B. Fasting, feeding, and the regulation of the sympathetic nervous system. N Engl J Med. 1978;298:1295-1301.

12. Verwaerde P., Senard J.M., Galiener M. et al. Changes in short-term variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. J Hypertension. 1999; 17:1135-1143.

13. O'Dea K., Esler M., Leonard P., Stockigt J.R., Nestel P. Noradrenaline turnover during under-and over-eating in normal weight subjects. Metabolism. 1982;31:896-899.

14. Di Bona G.F. Sympathetic neural control of the kidney in hypertension. Hypertension. 1992; 19:I-28-I-35.

15. Haynes W.G., Sivitz W.I., Morgan D.A. et al. Sympathetic and cardiac actions of leptin. Hypertension. 1997;30:619-623.

16. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension. 1992;19:161-166.

17. Baskin D.G., Figlewicz D.P., Woods S.C. et al. Insulin in the brain. Ann Rev Physiol. 1987;49:335-347.

18. Masuo K., Mikami H., Ogihara T., Tuck M.L. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young nonobese Japanese population. Am J Hypertens. 1997;10:77-83.

19. Kaaja J., Poyhonen-Alho M.K. Insulin resistance and sympathetic overactivity in women. J Hypertension. 2006;24:131-141.

20. O'Hare J.A., Minaker K.L., Meneilly G.S., Rowe J.W., Pallotta J.A., Young J.B. Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. Metabolism. 1989;38:322-329.

21. Carretta R., Fabris B., Fischetti F., Costantini M., et al. Reduction of blood pressure in obese hyperinsulinemic hypertensive patients during somatostatin infusion. J Hypertens. 1989;7(Suppl 6):S196-197.

22. Grassi G., Colombo M., Seravalle G. et al. Dissociation between muscle and skin sympathetic nerve activity in hypertension, obesity, and heart failure. Hypertension. 1998;31:896-899.

23. Grassi G., Servalle G., Dell'Oro R. et al. Participation of the hypothlamus-hypophysys axis in the sympathetic activation of human obesity. Hypertension. 2001;38:1316-1320.

24. Grassi G., Dell'Oro R., Quarto-Trevano F. et al. Noradrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005; 48:1359-1365.

25. Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546-2553.

26. Iwashima Y., Katsuya T., Ishikawa K. et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-1323.

27. Paquali R., Cantobelli S., Casimirri F. et al. The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal fat distribution. Metabolism. 1992;41:763-767.

28. McCubbin J.A., Survit R.S., Williams R.B., Nemeroff C.B., McNeilly M. Altered pituitary hormone response to naloxone in hypertension development. Hypertension. 1989;14:636-644.

29. Young T., Palta M., Dempsey J. et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230-1235.

30. Wilcox I., McNamara S.G. et al. "Syndrom Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax. 1998;53(Suppl. 3): S5-S28.

31. Somers V.K., Dyken M.E., Clary M.P., Abboud F.M. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin. Invest. 1995;96:1897-1904.

32. Narkiewicz K., van de Borne P.J., Montano N. et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation. 1998;97:943-945.

33. Phillips B.G., Kato M., Narkiewicz K., Choe I., Somers V.K. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J Physiol. Heart Circ. Physiol. 2000;279:H234-237.

34. Narkiewicz K., Montano N., Cogliati C. et al. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98:1071-1077.

35. Somers V.K. Debating sympathetic overactivity as hallmark of human obesity: an opposing position. J Hypertens. 1999;17:1061-1064.

36. Scott M. Grundy A. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature Reviews 2006;5:295-304.

37. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists: beyond the renin-angiotensin system. J Hypertension. 2004:2253-2261.

38. Lindholm L.H., Ibsen T., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet. 2002;359:1004-1010.

39. Rosen P., Ohly P., Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens. 1997;15(Suppl. 1):S31-S38.

40. Penicaud L., Berthault M.F., Morin J. et al. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl. 1998;16:S45-S49.

41. Kaan E.C., Brckner R., Frohly P. et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc. Risk Factors. 1995;5(Suppl 2):S29-S35.

42. Haenni A., Litchel H. Moxonidine improves insulin sensitivity in insulin resistant hypertensives. J Hypertens. 1999;17(Suppl. 3):S29-35.

43. Pillion G., Fevrier B., Codis P., Schutz D. Long-term control of blood pressure by rilmenidine in high-risk populations. Am J Cardiol. 1994;74:58A-65A.

44. Almazov V.A., Shlyakto E.V., Krasilnikova E.A. et al. Insulin resitsnce and arterial hypertension. The influence of moxonidine therapy. J Hypertens. 2000;18(Suppl 2):S12.

45. Chazova I.E., Almazov V.A. and Shlyakhto E.V. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obesity and Metabolism. 2006;8(4):456.

46. Scemama M., Fevrier B., Beucler I., Dairou R. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. J Cardiovasc Pharacol. 1995;26(Suppl 2):S34-S39.

47. De Luca N., Izzo R., Fontana D. et al. Hemodynamic and metabolic effect of rilmenidine in hypertensive patients with metabolic syndrome X. A Double-Blind Parallel Study versus amlodipine. J Hypertens. 2000;18:10.

48. Anichkov D.A., Shastak N.A., Schastnaya O.V. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipids and glucose levels in hypertensive women with metabolic syndrome. Curr Med. Res. 2005;21:113-119.

49. Sanjuliani A.F., de Abreu V.G., Francischetti E.A. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int. J. Clin. Pract. 2006;60:621-629.

50. Sharma A.M., Wagner T., Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J. Human. Hypertens. 2004;18:669-675.

51. Шляхто Е.В., Конради А.О. Динамика массы тела, уровней глюкозы и липидов плазмы на фоне приема рилменидина в монотерапии и в комбинации с амлодипином (по результатам исследования АЛЬТАИР). // Артериальная гипертензия. 2006. Т. 12, № 2. C. 67-71.

52. Bell-Anderson K.S., Bryson J.M. Leptin as a potential treatment for obesity: progress to date. Treat Endocrinol. 2004;3:11-18.


Для цитирования:


Konradi A.O. Симпатическая нервная система, ожирение и артериальная гипертензия. Возможности терапии. Ожирение и метаболизм. 2007;4(3):9-15. https://doi.org/10.14341/2071-8713-5016

For citation:


. Simpaticheskaya nervnaya sistema, ozhirenie i arterial'naya gipertenziya. Vozmozhnosti terapii. Obesity and metabolism. 2007;4(3):9-15. (In Russ.) https://doi.org/10.14341/2071-8713-5016

Просмотров: 12


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)